Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy
Authors:
Open Access
- 1 December 2015
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 122 (12) , 2504-2513.e1
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Two-Year Safety and Efficacy of Ranibizumab 0.5 mg in Diabetic Macular EdemaOphthalmology, 2013
- Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III TrialsOphthalmology, 2013
- Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and ProgressionArchives of Ophthalmology (1950), 2012
- Ranibizumab for Diabetic Macular EdemaOphthalmology, 2012
- The RESTORE StudyOphthalmology, 2011
- Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2011
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)Diabetes Care, 2010
- Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) StudyOphthalmology, 2010
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010
- Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) StudyOphthalmology, 2009